These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 21315472)

  • 1. Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma.
    Uramoto H; Shimokawa H; Hanagiri T; Kuwano M; Ono M
    Lung Cancer; 2011 Sep; 73(3):361-5. PubMed ID: 21315472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI.
    Uramoto H; Yamada T; Yano S; Kondo N; Hasegawa S; Tanaka F
    Anticancer Res; 2012 Sep; 32(9):3785-90. PubMed ID: 22993320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status.
    Onitsuka T; Uramoto H; Ono K; Takenoyama M; Hanagiri T; Oyama T; Izumi H; Kohno K; Yasumoto K
    J Thorac Oncol; 2010 May; 5(5):591-6. PubMed ID: 20150826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma.
    Uramoto H; Iwata T; Onitsuka T; Shimokawa H; Hanagiri T; Oyama T
    Anticancer Res; 2010 Jul; 30(7):2513-7. PubMed ID: 20682976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alteration of the E-cadherin/β-catenin complex predicts poor response to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment.
    Yoo SB; Kim YJ; Kim H; Jin Y; Sun PL; Jheon S; Lee JS; Chung JH
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S545-52. PubMed ID: 23579873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status.
    Onitsuka T; Uramoto H; Nose N; Takenoyama M; Hanagiri T; Sugio K; Yasumoto K
    Lung Cancer; 2010 May; 68(2):198-203. PubMed ID: 19589612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer.
    Suda K; Murakami I; Sakai K; Tomizawa K; Mizuuchi H; Sato K; Nishio K; Mitsudomi T
    Lung Cancer; 2016 Jan; 91():36-40. PubMed ID: 26711932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.
    Yano S; Yamada T; Takeuchi S; Tachibana K; Minami Y; Yatabe Y; Mitsudomi T; Tanaka H; Kimura T; Kudoh S; Nokihara H; Ohe Y; Yokota J; Uramoto H; Yasumoto K; Kiura K; Higashiyama M; Oda M; Saito H; Yoshida J; Kondoh K; Noguchi M
    J Thorac Oncol; 2011 Dec; 6(12):2011-7. PubMed ID: 22052230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment and biological characteristics of acquired gefitinib resistance in cell line NCI-H1975/gefinitib-resistant with epidermal growth factor receptor T790M mutation.
    Zhao BX; Wang J; Song B; Wei H; Lv WP; Tian LM; Li M; Lv S
    Mol Med Rep; 2015 Apr; 11(4):2767-74. PubMed ID: 25483995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
    Matsumoto Y; Maemondo M; Ishii Y; Okudera K; Demura Y; Takamura K; Kobayashi K; Morikawa N; Gemma A; Ishimoto O; Usui K; Harada M; Miura S; Fujita Y; Sato I; Saijo Y;
    Lung Cancer; 2014 Nov; 86(2):195-200. PubMed ID: 25249428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
    Jeannot V; Busser B; Brambilla E; Wislez M; Robin B; Cadranel J; Coll JL; Hurbin A
    Int J Cancer; 2014 Jun; 134(11):2560-71. PubMed ID: 24374738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRKL amplification is rare as a mechanism for acquired resistance to kinase inhibitors in lung cancers with epidermal growth factor receptor mutation.
    Suda K; Mizuuchi H; Murakami I; Uramoto H; Tanaka F; Sato K; Takemoto T; Iwasaki T; Sekido Y; Yatabe Y; Mitsudomi T
    Lung Cancer; 2014 Aug; 85(2):147-51. PubMed ID: 24939008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
    Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
    J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
    Rho JK; Choi YJ; Lee JK; Ryoo BY; Na II; Yang SH; Lee SS; Kim CH; Yoo YD; Lee JC
    Mol Cancer Res; 2009 Oct; 7(10):1736-43. PubMed ID: 19808904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.
    Suda K; Tomizawa K; Fujii M; Murakami H; Osada H; Maehara Y; Yatabe Y; Sekido Y; Mitsudomi T
    J Thorac Oncol; 2011 Jul; 6(7):1152-61. PubMed ID: 21597390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical implications of high MET gene dosage in non-small cell lung cancer patients without previous tyrosine kinase inhibitor treatment.
    Chen YT; Chang JW; Liu HP; Yu TF; Chiu YT; Hsieh JJ; Chen YT; Chen YR; Wu HD; Huang SF
    J Thorac Oncol; 2011 Dec; 6(12):2027-35. PubMed ID: 22052229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.
    Yano S; Wang W; Li Q; Matsumoto K; Sakurama H; Nakamura T; Ogino H; Kakiuchi S; Hanibuchi M; Nishioka Y; Uehara H; Mitsudomi T; Yatabe Y; Nakamura T; Sone S
    Cancer Res; 2008 Nov; 68(22):9479-87. PubMed ID: 19010923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer.
    Yamada T; Matsumoto K; Wang W; Li Q; Nishioka Y; Sekido Y; Sone S; Yano S
    Clin Cancer Res; 2010 Jan; 16(1):174-83. PubMed ID: 20008840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
    Okabe T; Okamoto I; Tsukioka S; Uchida J; Hatashita E; Yamada Y; Yoshida T; Nishio K; Fukuoka M; Jänne PA; Nakagawa K
    Clin Cancer Res; 2009 Feb; 15(3):907-13. PubMed ID: 19188161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny.
    Suda K; Mizuuchi H; Maehara Y; Mitsudomi T
    Cancer Metastasis Rev; 2012 Dec; 31(3-4):807-14. PubMed ID: 22736441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.